ABVC BioPharma Inc (ABVC) USD0.001
ABVC BioPharma, Inc. (ABVC), formerly American BriVision (Holding) Corporation, is a biotechnology company focused on the development of drugs and medical devices. The Company is focused on developing its pipeline by tracking medical discoveries or medical device technologies in research institutions. ABVC has approximately six drugs and three medical devices in development. The Company's pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1702, ABV-1703, ABV-1601, ABV-1701, ABV-2001 and ABV-2002. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine. ABVC is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). ABV-1702 is to treat myelodysplastic syndromes (MDS). ABVC developed an indication, ABV-1703, for Pancreatic Cancer. The Company has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.